IDEAYA Biosciences, Inc.

Annual Trend FY 2011 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $23.8m
$0 -100.00%
$2.1m
$2.3m +10.86%
$19.5m +750.96%
$27.9m +43.01%
$50.9m +82.28%
$23.4m -54.08%
$7.0m -70.07%
$218.7m +3024.43%
$234.1m +7.05%
Research and development $12.4m $31.7m $34.3m $39.7m $58.2m $89.5m $129.5m $294.7m $314.7m $374.0m
General and administrative ($4.5m) $2.1m $4.7m $10.0m $15.2m $20.1m $23.9m $28.3m $39.3m $63.3m $77.1m
Operating Lease, Expense $1.5m $1.5m $1.7m $1.7m
Operating Expenses $14.4m $36.4m $44.3m $54.9m $78.2m $113.4m $157.8m $334.0m $378.0m $451.1m
Loss from operations $1.7m
($14.4m) -930.34%
($36.4m) -152.23%
($44.3m) -21.57%
($35.3m) +20.16%
($50.3m) -42.22%
($62.5m) -24.34%
($134.4m) -115.08%
($327.0m) -143.23%
($159.3m) +51.28%
Operating Income (Loss) $1.7m
($14.4m) -930.34%
($36.4m) -152.23%
($44.3m) -21.57%
($35.3m) +20.16%
($50.3m) -42.22%
($62.5m) -24.34%
($134.4m) -115.08%
($327.0m) -143.23%
($159.3m) +51.28%
($217.0m) -36.18%
Interest income and other income, net $2.1m $2.3m $849k $506k $3.8m $21.5m $52.5m $45.6m $41.9m
Other Nonoperating Income (Expense) $77k $8k
Pre-Tax Income ($3.1m) ($11.9m) ($34.3m) ($42.0m) ($34.5m) ($49.8m) ($58.7m) ($113.0m) ($274.5m) ($113.7m) ($175.0m)
Income Tax Expense (Benefit) $0 $0 $0 $0 $0 $0
Net loss ($3.1m) ($11.9m) ($34.3m) ($42.0m) ($34.5m) ($49.8m) ($58.7m) ($113.0m) ($274.5m) ($113.7m)
Net Income From Continuing And Discontinued Operation ($3.1m) ($11.9m) ($34.3m) ($42.0m) ($34.5m) ($49.8m) ($58.7m) ($113.0m) ($274.5m) ($113.7m) ($175.0m)
Otherunder Preferred Stock Dividend $719k $2.2m
Earnings Per Share, Basic ($0.24) ($1.42) ($1.96) ($3.36) ($1.28) ($1.92)
Earnings Per Share, Diluted ($0.24) ($1.42) ($1.96) ($3.36) ($1.28) ($1.92)
Weighted Average Number of Shares Outstanding, Basic 41.4m 57.5m 81.7m 88.5m 89.5m
Basic Average Shares $41.4m $57.5m $81.7m $88.5m $89.5m
Diluted Average Shares $41.4m $57.5m $81.7m $88.5m $89.5m
Weighted Average Number of Shares Outstanding, Diluted 41.4m 57.5m 81.7m 88.5m 89.5m
Additional Financial Items
Unrealized gains on marketable securities ($1k) ($30k) $96k ($58k) ($719k) ($2.2m) $3.4m $250k $1.5m
Comprehensive loss ($11.9m) ($34.4m) ($41.9m) ($34.6m) ($50.5m) ($60.8m) ($109.5m) ($274.2m) ($112.2m)
Depreciation and amortization ($81k)
Diluted EPS ($0.24) ($1.42) ($1.96) ($3.36) ($1.28) ($1.92)
Diluted NI Availto Com Stockholders ($3.1m) ($11.9m) ($34.3m) ($42.0m) ($34.5m) ($49.8m) ($58.7m) ($113.0m) ($274.5m) ($113.7m) ($175.0m)
Normalized EBITDA ($59.0m) ($130.4m) ($323.1m) ($154.7m) ($212.5m)
Normalized Income ($3.1m) ($11.9m) ($34.3m) ($42.0m) ($34.5m) ($49.8m) ($58.7m) ($113.0m) ($274.5m) ($113.7m) ($175.0m)
Other Gand A ($4.5m) $2.1m $4.7m $10.0m $15.2m $20.1m $23.9m $28.3m $39.3m $63.3m
Reconciled Depreciation $3.5m $4.0m $3.8m $4.6m $4.5m
Selling General And Administration ($4.5m) $2.1m $4.7m $10.0m $15.2m $20.1m $23.9m $28.3m $39.3m $63.3m
Tax Effect Of Unusual Items $0 $0 $0 $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0 $0 $0 $0
Total Expenses $14.4m $36.4m $44.3m $54.9m $78.2m $113.4m $157.8m $334.0m $378.0m $451.1m